Neurology

1898–1927 · 1 of 9

Cortical Localization and CSF

1898–1927

Cortical Localization and CSF

Contemporary themes

During the 1898-1927 window, neuroscience coalesced around precise localization of cerebral function through detailed histology and cortical mapping, tying neuronal architecture to specific neurological abilities. A cerebrospinal fluid–centered program emerged, guiding inquiry into origin, circulation, and homeostatic roles of the cerebrospinal fluid in brain health. Concurrently, pathology-driven neuro-oncology and cross-species neurophysiology fostered an integrated approach to nervous system disorders and a budding taxonomy that linked psychiatric syndromes with CNS disease and development across species.

  • Anatomical mapping of CNS structure and cellular composition through early histology and nerve anatomy, linking neurone organization, ependymal lining, and cranial nerve pathways to neurological function.
  • CSF-centric neuroscience emerges as a core paradigm, tracing cerebrospinal fluid origin, circulation, and composition, and its relation to brain homeostasis across several studies.
  • Pathology-driven neuro-oncology threads converge on recognizing CNS tumors and neural cell lineages, from neurofibroma and neuroblastoma to medulloblastoma, informing early tumor taxonomy, with broader nervous-system disease context.
  • Cross-species neurophysiology embraces animal models to probe sympathetic circuits, brain development, and metabolic effects, linking trunk nerves, ganglia, and CNS energy states to nervous system function.
  • Clinical neurology combines psychiatric syndromes with CNS disease taxonomy, seen in dementia praecox and manic-depressive illness, and case reports of neurodegenerative musculoskeletal neuropathies, shaping early clinical categorization.

Influential works

Foundational publications unified cellular, cortical, and topographical perspectives to seed modern functional neuroanatomy. Histologie du système nerveux de l'homme & des vertébrés (1909) and Histological Studies on the Localisation of Cerebral Function (1904) established the neuron doctrine and localization principles, while A New Topographical Survey of the Human Cerebral Cortex (1907) offered practical cortical maps for clinical and surgical use. Additional syntheses on sensory localization and epilepsy informed standardized neurological examination and taxonomy, shaping decades of neuroscience research.

  • Histologie du système nerveux de l'homme & des vertébrés (1909) established the neuron doctrine via detailed cellular wiring and Golgi-staining observations, arguing that discrete neurons are functional units and laying the foundation for modern neuroanatomy; its influence guided neuroscience for decades.
  • Histological Studies on the Localisation of Cerebral Function (1904) presented early evidence for localized cortical functions, challenging diffuse brain models and laying groundwork for targeted mapping that shaped subsequent localisation debates and modern functional anatomy.
  • A New Topographical Survey of the Human Cerebral Cortex, being an Account of the Distribution of the Anatomically Distinct Cortical Areas and their Relationship to the Cerebral Sulci. (1907) offered a practical atlas of cortical areas aligned with sulci, guiding early surgical localization and underpinning Brodmann’s later cortical-area concepts.
  • SENSORY DISTURBANCES FROM CEREBRAL LESIONS (1911) systematically linked sensory deficits to specific cortical regions, refining clinical localization and contributing to standardized neurological examination and diagnosis.
  • Epilepsy and other Chronic Convulsive Diseases, Their Causes, Symptoms and Treatment (1902) compiled contemporary theories of epilepsy, influencing classification and early treatment strategies and shaping neurology’s clinical and research agenda for years.

1928–1953

Neurovascular Circuitry Mapping

Contemporary themes

The period saw neurovascular regulation emerge as a central substrate linking epilepsy, ischemia, and traumatic injury, with studies mapping cerebral blood flow, vasodilator pathways, and vascular networks to explain brain dysfunction. Electroencephalography and neurophysiological classification provided a unifying diagnostic frame, standardizing waveforms and paroxysmal patterns from dysrhythmia to impaired consciousness. Advances in neural circuitry mapping and histology—spanning hypothalamic–spinal pathways, amygdaloid complexes, and telencephalon organization—were complemented by degeneration, regeneration, and neuroimmunology work, and by trauma and surgical repair research that tied injury to repair strategies.

  • Vascular regulation and cerebral hemodynamics emerge as a central substrate linking epilepsy, ischemia, and traumatic injury, with works mapping cerebral blood flow, vasodilator pathways, and spinal/cranial vascular networks.
  • Electroencephalography and neurophysiological classification of epilepsies provide a unifying methodological frame for diagnosis and understanding brain dysfunction, from paroxysmal dysrhythmia to impaired consciousness.
  • Neural circuitry and brain structure mapping—hypothalamic–spinal pathways, amygdaloid complexes, and telencephalon organization—frame functional organization and clinical pathology.
  • Degeneration, regeneration, and neuroimmunology reveal fundamental processes shaping nervous system aging and pathology, including neurodegenerative paradigms and encephalomyelitic models.
  • Trauma, injury, and surgical repair constitute a dominant thread, linking traumatic epilepsy, intracranial injuries, and peripheral nerve repair strategies.

Influential works

Collectively these works established the neurovascular-circuitry integration as a unifying paradigm, setting the stage for later developments in neurophysiology, histology, and neurosurgery. They provided enduring methodological innovations—electroencephalography mapping, paraffin-compatible staining, and combined staining protocols—that enabled future exploration of brain function, circuitry, and repair, shaping neuroscience through mid-century.

  • Degeneration and Regeneration of the Nervous System (1929) offered the first comprehensive synthesis of how neurons degenerate after injury and their limited regenerative capacity, detailing Wallerian-type processes and glial contributions, shaping early neurobiology and repair research.
  • Atlas of Electroencephalography (1941) provided a systematic atlas of EEG patterns mapping regional brain activity, standardizing waveforms and abnormalities, and catalyzing EEG-based diagnosis, sleep research, and later cognitive neuroscience.
  • A new method for staining nerve fibers and nerve endings in mounted paraffin sections (1936) introduced a paraffin-compatible staining technique that visualizes both fibers and endings, greatly improving histology and enabling detailed neural circuitry mapping.
  • Dendritic organization in the neurons of the visual and motor cortices of the cat (1953) offered one of the first systematic descriptions of dendritic trees in cortical neurons, informing models of cortical integration and guiding subsequent morphometric analyses.
  • A Method for the Combined Staining of Cells and Fibers in the Nervous System (1953) described a dual-staining protocol enabling simultaneous visualization of cell bodies and fiber tracts, becoming a staple technique for mapping mammalian neural circuits.

1954–1960

Cortical Functional Localization

Contemporary themes

During 1954-1960, neuroscience advanced toward a unified functional neuroanatomy by integrating direct cortical stimulation, standardized electroencephalography, and fine-scale cellular architecture. The dominant paradigm treated cortical regions as modular units with defined roles, while attention to limbic circuits and thalamocortical connections shaped emotion, memory, and action. Methodologies combining epilepsy-based functional mapping, atlas-building, histochemical localization, and ultrastructural imaging anchored a coherent framework that informed neurosurgical planning and diagnostic neuroscience.

  • Neural connectivity and limbic circuitry across corticolimbic networks, emphasizing anatomical and electrophysiological organization of the amygdaloid projection system, limbic lobe, and thalamic/pontine connections that shape emotion, memory, and motor planning. Assisted by work on amygdaloid projections, limbic cortex, thalamic connexions, and corticobulbar pathways.
  • Vascular and metabolic mechanisms of CNS injury and stroke, tracing collateral flow, arterial occlusion, and hypernatremic lesion pathogenesis to connect vascular physiology with tissue necrosis and infant brain vulnerability. Foundations in collateral circulation, vessel compression, MCA occlusion, and hypernatremia pathology.
  • Neurophysiology and ultrasound-based modulation of brain function, integrating cerebellar physiology with ultrasound-induced reversible and focal destructive CNS changes to illuminate noninvasive interventional paradigms and neuromodulation effects. Includes cerebellar physiology and ultrasound effects on CNS physiology and lesions.
  • Neuropathology resources, imaging, and lesion characterization to build structural understanding, combining atlas-based neuroanatomy with silver degeneration methods and temporal lobe epilepsy pathology for lesion mapping and diagnostic reference. Represented by Atlas of Neuropathology, silver degeneration methods, and temporal lobe epilepsy pathology.

Influential works

This era established enduring standards in brain mapping and tissue characterization. The introduction of systematic electrical stimulation mapping and standardized EEG protocols provided reproducible, cross-site measures that propelled research and clinical practice. Detailed ultrastructure and cholinesterase mapping opened pathways to neurochemical and cellular-level understanding of signaling. Together, these advances created foundational knowledge and tools that guided subsequent exploration of brain function, organization, and pathology.

  • Epilepsy and the Functional Anatomy of the Human Brain (1954) introduced systematic electrical stimulation mapping in epileptic patients, establishing localized cortical function concepts and the inspiration for the Penfield homunculus, which shaped neurosurgical planning and neuroscientific localization for decades.
  • Report of the committee on methods of clinical examination in electroencephalography (1958) formalized standardized EEG examination protocols, nomenclature, and interpretation criteria, enabling cross-site comparability, replication, and rapid integration of EEG into neurological diagnosis and research.
  • The histochemical localization of cholinesterases in the central nervous system of the rat (1954) provided early histochemical mapping of cholinesterase activity, illuminating cholinergic pathways and enabling subsequent neurochemical studies of brain signaling and disease.
  • The Fine Structure of Neurons (1955) offered the first detailed ultrastructural description of neuronal components, synapses and organelles using electron microscopy, laying groundwork for modern neuroanatomy and bridging cellular biology with brain function.

1961–1979

Monoaminergic Circuit Atlas

Contemporary themes

The Neurology period from 1961 to 1979 established the monoaminergic system as the central organizing framework for brain function, unifying diverse circuits through brain-wide mapping of dopamine, norepinephrine, and serotonin pathways. Through autoradiography, silver impregnation, and stereotaxic coordinates, researchers charted terminal distributions and projection patterns, while hippocampal and limbic connectivity was decoded to reveal core limbic circuits linking memory and affect. Functional neurophysiology further showed how targeted brainstem stimulation and monoaminergic signaling modulated sensory processing and emotional behavior, supported by innovative neuroanatomical techniques that enabled systematic circuit atlases across rodent brains.

  • Monoaminergic system mapping across the CNS emerges as a unifying theme, with autoradiography, silver impregnation, and stereotaxic methods delineating dopamine and noradrenaline pathways, terminal distributions, and projection patterns, establishing brain-wide monoaminergic organization.
  • Hippocampal and limbic connectivity is decoded through silver impregnation and autoradiography, mapping commissural/ipsilateral connections, perforant path origins/terminations, and amygdaloid-cortex projections, revealing core limbic circuits.
  • Functional neurophysiology reveals how targeted brainstem stimulation and monoaminergic pathways modulate sensory and affective processing, linking analgesia and neurochemical circuits to behavioral outcomes.
  • Methodological innovations in neuroanatomy, including cupric-silver and silver impregnation techniques, autoradiography, and stereotaxic mapping, enabled systematic circuit atlases and comparative neuroanatomy across rodent brains.

Influential works

This era produced landmark breakthroughs that solidified a cell- and circuit-based view of neurology. Demonstrations that monoamines exist in brainstem cell bodies provided a cellular basis for widespread monoaminergic influence and catalyzed targeted pharmacology and circuit mapping. Pioneering stereotaxic atlases of the rat brain offered standardized coordinates for reproducible experimentation, while studies foregrounding dopamine’s role connected clinical syndromes such as Parkinson’s and Huntington’s to neurochemical pathways. Parallel work on cholinergic degeneration anchored dementia theories and steered future therapeutic strategies. Collectively, these advances laid the groundwork for modern circuit neuroscience by forging robust maps of neuromodulatory systems and their behavioral relevance.

  • "EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. Demonstration of monoamines in the cell bodies of brain stem neurons." (1964) This landmark result showed monoamines present in neuronal cell bodies, not only terminals, establishing a cellular basis for monoaminergic signaling and enabling systematic mapping and pharmacological exploration of NE, DA, and 5-HT systems.
  • "Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats" (1965) This early claim challenged the belief that neurogenesis ceases after development, providing radiographic/histological support for hippocampal plasticity and shaping decades of research into learning, memory, aging, and brain repair.
  • "A stereotaxic atlas of the rat brain" (1967) The first comprehensive, standardized rat brain atlas offered precise coordinates for brain regions, enabling reproducible lesioning, electrophysiology, and anatomy studies, cornerstone for many subsequent experimental neuroscience advances.
  • "Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations" (1973) This synthesis integrated clinical presentation with neurochemical data to position dopamine as central to PD and Huntington's, catalyzing targeted therapies and driving long-term basal ganglia circuit research.
  • "SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE" (1976) By showing specific cholinergic neuron loss, this work anchored the cholinergic hypothesis of dementia and propelled cholinesterase inhibitor research, profoundly shaping diagnostics and treatment approaches.

1980–1986

Cholinergic Degeneration and Ischemia

Contemporary themes

The period was defined by a dual emphasis on cholinergic degeneration and ischemic injury as central drivers of cognitive decline. Work delineated basal forebrain cholinergic loss, especially in the nucleus basalis Meynert, and linked it with shared cholinergic/noradrenergic vulnerability across dementias, while ischemia-focused research charted penumbra dynamics and neuroprotective strategies such as NMDA receptor blockade. Across these threads, foundational neuroanatomy and early amyloid pathology research provided essential scaffolding for interpreting structure-function relationships in aging and dementia.

  • Cholinergic system degeneration, centered on basal forebrain and Meynert nucleus neurons, emerges as a core neuropathological axis in Alzheimer's and related dementias, linking selective neuronal loss to cognitive decline.
  • Ischemia-driven neuronal injury and neuroprotection strategies prevail across animal models and neuroimaging, with delayed neuronal death, penumbra concepts, and NMDA receptor blockade highlighting protective interventions.
  • Foundational neuroanatomy and connectivity mapping provide essential scaffolding for functional and disease studies, via rodent brain atlases, efferent connectivity, and morphometric brain analyses.
  • Amyloid pathology anchors early dementia research, with amyloid deposits revealing degenerative processes and Alzheimer's disease biology.
  • Nucleus basalis Meynert and locus coeruleus vulnerability across dementias suggests a shared cholinergic/noradrenergic substrate for cognitive decline.

Influential works

Several breakthroughs defined the era. First, it was shown that selective loss of basal forebrain cholinergic neurons accompanies Alzheimer's disease, reinforcing the cholinergic deficit hypothesis. Second, the ischemia literature established the ischemic penumbra concept, shaping stroke care and neuroprotection strategies, while parallel work laid groundwork for standardized Alzheimer's diagnosis and dementia staging.

  • Thresholds in cerebral ischemia - the ischemic penumbra (1981) introduced the concept of a salvageable zone around the infarct, defining tissue at risk that could be saved by reperfusion, shaping stroke research and acute management for decades.
  • Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis (1983) revealed that a synthetic meperidine derivative (MPTP) caused rapid-onset parkinsonism in humans, providing the path to the MPTP model and exposing dopaminergic vulnerability.
  • Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain (1982) demonstrated selective neuronal loss in basal forebrain, supporting the cholinergic deficit hypothesis and guiding later cholinergic-targeted therapies.
  • Clinical diagnosis of Alzheimer's disease (1984) established standardized diagnostic criteria for Alzheimer's disease, enabling consistent clinical diagnosis and research, and setting the stage for future refinements in diagnostic frameworks.
  • The Global Deterioration Scale for assessment of primary degenerative dementia (1982) introduced a global staging framework to quantify dementia severity, improving clinical assessment, prognosis, and comparability across studies.

1987–1993

Molecular Neurodegeneration and Neuroprotection

Contemporary themes

Neurology research during 1987–1993 coalesced around a unifying neurodegenerative paradigm that links molecular pathology, energy metabolism, and proteopathic processes. Parkinson's disease pathophysiology was framed as a convergence of nigral iron accumulation, lipid peroxidation, mitochondrial dysfunction, and uneven dopaminergic loss that accompanies Lewy body pathology. Alzheimer-type pathology emphasized protein aggregation with apolipoprotein E acting as a chaperone for amyloid, while neurotrophic signaling—especially Brain-Derived Neurotrophic Factor and Neurotrophin-3—emerged as central to dopaminergic neuron survival; glutamate excitotoxicity and ischemia highlighted injury pathways that directed early neuroprotective strategies using NMDA receptor antagonists and NBQX-like agents.

  • Parkinson's disease pathophysiology emerges as a convergent theme, linking nigral iron accumulation, lipid peroxidation, mitochondrial electron transport chain deficits, and uneven dopaminergic loss with Lewy body pathology across multiple postmortem and imaging-inferred studies.
  • Molecular pathology and protein aggregation are central across Alzheimer's and related amyloid disorders, with ubiquitin in neurofibrillary tangles, Alzheimer's molecular pathology, and Apolipoprotein E as a pathological chaperone for amyloid.
  • Neurotrophic signaling underpins neuronal survival and development, highlighted by Neurotrophin-3 and Brain-Denefactor? Wait. Correction: Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 are implicated in dopaminergic neuron survival, supporting trophic strategies in neurodegenerative contexts.
  • Glutamate excitotoxicity and ischemia drive injury and guide neuroprotective strategies, with evidence for glutamate toxicity in CNS diseases, and protective effects of N-methyl-D-aspartate (NMDA) receptor antagonists and NBQX-like agents, plus ischemia physiology factors.

Influential works

Cross-period breakthroughs identified Cu/Zn superoxide dismutase gene mutations as a cause of familial ALS, catalyzing animal models and mechanistic studies that shaped neurodegenerative research for years. The Amyloid Cascade Hypothesis for Alzheimer's disease articulated a unifying role for amyloid-beta, guiding biomarker development and therapeutic directions; the reversible middle cerebral artery occlusion model in rats enabled controlled study of focal ischemia and neuroprotection; and the Positive and Negative Syndrome Scale for schizophrenia provided standardized clinical endpoints and trial design that influenced research practices across disciplines.

  • Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis (1993) identified SOD1 mutations as a genetic cause, establishing the genetic basis of ALS and catalyzing animal models, mechanistic studies, and targeted therapies that shaped the field for decades.
  • Alzheimer's Disease: The Amyloid Cascade Hypothesis (1992) proposed that amyloid-beta initiates Alzheimer's pathology, unifying sporadic and familial disease and guiding biomarker development, imaging, and therapeutic strategies for decades.
  • Reversible middle cerebral artery occlusion without craniectomy in rats (1989) introduced a reversible, non-craniectomy MCAO model in rats, enabling controlled study of focal cerebral ischemia and neuroprotective interventions, catalyzing preclinical stroke research and translational testing.
  • The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia (1987) provided a standardized, comprehensive rating of schizophrenia symptoms, shaping diagnosis, trial endpoints, and cross-cultural research, and influencing psychiatric assessment for years.

1994–2010

Alpha-Synuclein Pathobiology in Parkinson's

Contemporary themes

During this period, researchers converged on alpha-synuclein pathobiology as a central driver of Parkinson's disease and related synucleinopathies, linking misfolding, Lewy body formation, and clinical progression. Quality control via the ubiquitin-proteasome system and Parkin-mediated ubiquitination was established as a key regulator of alpha-synuclein turnover, with disruptions correlating with aggregation and pathology. Staging and diagnostic criteria anchored clinical syndromes to underlying brain pathology, while translational approaches such as deep brain stimulation and cell replacement began to demonstrate symptom relief and potential disease modification, and cross-disease amyloid mechanisms suggested shared targets across neurodegenerative diseases.

  • Genetic mutations and overexpression of α-Synuclein promote misfolding and Lewy body inclusion formation, positioning α-Synuclein pathobiology as a primary driver of Parkinson's disease and related synucleinopathies.
  • Protein quality control via the ubiquitin pathway and Parkin-mediated ubiquitination governs α-synuclein turnover; disruptions here correlate with aggregation, Lewy body formation, and PD pathology across multiple studies.
  • Neuropathology-guided staging and diagnostic criteria unify clinical Parkinson's syndrome with underlying brain pathology, enabling correlates of disease progression and heterogeneity across studies.
  • Translational therapies bridge bench and clinic: deep brain stimulation and cell replacement approaches demonstrate symptomatic relief and potential disease modification in Parkinson's disease.
  • Amyloid-related pathology and aging converge across neurodegenerative diseases, highlighting cross-disease mechanisms and potential shared therapeutic targets in amyloid and synucleinopathies.

Influential works

Landmark discoveries identified mutations in the alpha-synuclein gene and established alpha-synuclein as a central pathogenic driver. Evidence showing alpha-synuclein as a major component of Lewy bodies reframed the disease as a proteinopathy and directed aggregation-targeted therapies. The introduction of brain-pathology staging and progression mapping, along with formal recognition of mild cognitive impairment as a prodromal diagnostic entity, provided a framework linking biology to diagnosis and prognosis.

  • Insensitivity to future consequences following damage to the human prefrontal cortex (1994) introduced the somatic marker hypothesis and showed ventromedial prefrontal lesions impair value-based decision making, establishing a neurobehavioral basis for executive dysfunction and shaping frontal-lobe disorder research.
  • Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease (1997) documented SNCA mutations in PD families, establishing a genetic link and implicating α-synuclein in disease etiology, guiding genetic testing and early molecular investigations.
  • α-Synuclein in Lewy bodies (1997) showed alpha-synuclein is a major component of Lewy bodies, revealing a proteinopathy in Parkinson's disease and dementia with Lewy bodies, directing aggregation research and new therapeutic targets.
  • Staging of brain pathology related to sporadic Parkinson’s disease (2003) proposed Braak stages, mapping progressive Lewy body spread from olfactory regions to cortex, influencing diagnosis, prodromal studies, and biomarker strategies.
  • Mild cognitive impairment as a diagnostic entity (2004) formalized mild cognitive impairment as a prodromal stage to Alzheimer's disease, catalyzing standardized criteria, biomarker development, and trials targeting early cognitive decline.

2011–2017

Propagation-Driven Neurodegeneration

Contemporary themes

The period coalesced around a propagation-centric paradigm in which misfolded proteins spread in a prion-like manner between neurons, linking Lewy body diseases, tauopathies, and Alzheimer's disease through intercellular transmission of α-synuclein and tau and their interaction with amyloid-beta (Aβ). Exogenous seeds and network-wide propagation clarified initiation and dissemination of pathology, guiding strategies to interrupt transmission and target network vulnerability. Neurovascular and glymphatic clearance pathways—pericyte biology and paravascular cerebrospinal fluid flow—emerged as key modulators of amyloid clearance and neurovascular coupling, tying vascular dysfunction to neurodegeneration. Diagnostic standardization and pathology, together with biomarker integration within the amyloid/tau/neurodegeneration (A/T/N) framework enabled earlier staging for Alzheimer's disease and mild cognitive impairment and guided biomarker-driven trials; genetic and immune influences, including TREM2 variants and microglial polarization, highlighted disease heterogeneity and opened immunomodulatory avenues.

  • Prion-like propagation of misfolded proteins provides a unifying pathogenic framework across neurodegenerative diseases, with intercellular transmission of α-synuclein and tau driving Lewy body and tauopathies; exogenous fibrils and aggregates initiate pathology, propagate pathology across neural networks, and couple Aβ/tau dynamics in Alzheimer's models.
  • Neurovascular and glymphatic pathways modulate brain clearance, blood-brain barrier function, and neurodegeneration; pericyte biology and paravascular CSF flow regulate amyloid clearance and vascular-neural coupling, suggesting vascular contributions to cognitive impairment and neurodegenerative progression.
  • Standardization of diagnosis and neuropathology creates a framework for classification and biomarker integration in AD and MCI, guiding clinical criteria, preclinical staging, and practical pathologic assessment; this regulatory paradigm underpins trial design and translational progress.
  • Genetic and immune mechanisms, including TREM2 variants and microglial polarization, shape risk, progression, and inflammatory responses in neurodegeneration; these pathways explain heterogeneity and offer targets for immunomodulatory strategies.

Influential works

  • This 2011 paper on Alzheimer's disease (AD) diagnosis introduces biomarker-based criteria and the A/T/N framework, enabling earlier, more precise diagnosis and biomarker-driven trials.
  • Defines preclinical Alzheimer's disease (AD) stages using biomarker signatures (amyloid, neurodegeneration) to identify at-risk individuals, guiding prevention trials and early interventions.
  • Reiterates the amyloid hypothesis for Alzheimer's disease at 25 years, integrating evidence on Aβ, guiding drug development and trial design while fostering ongoing debate about timing and targets in AD.
  • Movement Disorder Society (MDS) criteria for Parkinson's disease refine motor and non-motor thresholds, set imaging supports, and standardize diagnosis, improving trial recruitment and cross-study comparisons.
  • Neurotoxic reactive astrocytes are induced by activated microglia demonstrates that microglial activation drives formation of A1 astrocytes, revealing a neuroinflammatory pathway to neuronal injury and guiding inflammation-focused Neurology research.

2018–2024

Biomarker-Driven Neurology Paradigm

Contemporary themes

The Neurology field from 2018 to 2024 was shaped by a biomarker-focused redefinition of neurodegenerative disease, integrating imaging and fluid biomarkers into a biology-based disease model and staging framework across preclinical to dementia stages using amyloid, tau, and neurodegeneration biomarkers (AT(N)). Inflammation and vascular biology emerged as central drivers, with microglia-neuron signaling, blood-brain barrier breakdown, and immune-vascular interactions highlighted as common nodes across diseases. Clinical-trial experience revealed translational gaps in disease-modifying strategies, as anti-amyloid approaches experienced setbacks while early anti-aggregation and mechanism-targeted strategies showed potential in earlier stages. The period also documented how systemic infection, notably coronavirus disease 2019, intersects neurology and cognition, shaping clinical management and long-term outcomes. Collectively, the period reflects a shift toward integrative biomarker biology, vascular-immune dysfunction, and cross-disciplinary translation that anchor modern neurology in biology-first thinking and early-detection paradigms.

  • Biomarker-centric redefinition and diagnostics of neurodegenerative disease, consolidating imaging and fluid biomarkers (Aβ, tau, neurofilaments) into a biology-based disease model and staging framework across preclinical to dementia stages.
  • Neuroinflammation, microglial biology, and vascular/blood-brain barrier dysfunction as core drivers of neurodegeneration, with mechanistic emphasis on microglia-neuron crosstalk, BBB breakdown, and neuronal death across diverse diseases.
  • Clinical trial evidence for disease-modifying strategies reveals translational gaps, with anti-amyloid approaches and other targets facing setbacks, while newer anti-aggregation strategies in early disease show potential.
  • Neurology of systemic infection and critical illness, with rapid documentation of diverse neurologic manifestations in COVID-19, illustrating how infectious disease intersects with neurology and cognitive outcomes.

Influential works

  • National Institute on Aging–Alzheimer's Association (NIA‑AA) Research Framework: Toward a biological definition of Alzheimer's disease introduced the AT(N) biomarker system to define AD by pathology (amyloid, tau, neurodegeneration) rather than clinical syndrome, catalyzing biomarker-driven research and early diagnosis uptake.
  • Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China offered early, comprehensive documentation of CNS involvement—encephalopathy, stroke, seizures—shaping urgent neurology research and guiding clinical management during the COVID-19 era.
  • Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders proposed BBB disruption as an early, common pathology across AD and related diseases, reframing research toward vascular, inflammatory mechanisms and candidate biomarkers and therapies.
  • Diagnosis and Treatment of Parkinson Disease delivers evidence-based guidance on diagnostic criteria, pharmacologic and non-pharmacologic therapies, and multidisciplinary care, influencing clinical practice and informing subsequent PD research and guidelines.
  • Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition updated diagnostic criteria for headache disorders, standardizing phenotyping and enabling robust epidemiology, trials, and cross-disciplinary research.